The impact of the results from low-risk TAVR trials will be felt for many years. It will be felt by a wide group - surgeons, cardiologists, hospital systems, insurance companies, and most importantly patients.
It was 8 am on a Thursday, and Nicholas Morrissey, MD, had already completed a proper morning. He taught residents from 6:15-7, attended a conference from 7-7:30, then met with his first patient in pre-op.
While it’s been around for years, TAVR was initially used as a last-chance option for people with highly severe aortic disease who wouldn’t be healthy enough to endure the intensity of a traditional surgery
The Columbia Pancreas Center is delighted to announce that our medical oncologist Gulam Manji, MD has been named the director of the newly established Pancreas Medical Oncology and Translational Research program.
March is colorectal cancer awareness month, and to help get the word out, Columbia colorectal surgeon Deborah Keller, MD is teaming up with the Colorectal Cancer Alliance for a Facebook live streaming event to answer your questions.